Recruiting
Phase 3

PET Imaging

Sponsor:

Lantheus Biosciences Ltd.

Code:

NCT05641688

Conditions

Alzheimer Disease

Eligibility Criteria

Sex: All

Age: 50+

Healthy Volunteers: Not accepted

Interventions

[18F]PI-2620

Study Details

Brief summary:

This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with \[18F\]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime when compared to histopathology obtained after death and completion of brain autopsy.

Conditions

Alzheimer Disease

Study ID

NCT05641688

Start date

Dec 1, 2022

Status verified date

Dec, 2025

Completion date

Jun, 2027

Anticipated

Primary completion date

Jun, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 50+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Only subjects who meet all of the following criteria will be eligible for enrollment into the study:

1. Males and females aged 50 years and over
2. Have a projected life expectancy of ≤ 1 year as determined by the investigator (terminal medical condition including but not limited to end-stage dementia, end-stage congestive heart failure, end-stage chronic obstructive pulmonary disease (COPD), or end-stage cancer)
3. Written informed consent obtained from the subject and/or the subject's legally authorized representative (LAR), as applicable, to consent for study procedures and brain donation (consent consistent with the legal requirements of the State in which the subject dies)
4. Can tolerate study procedures including lying down in PET scanner. The investigator will carefully assess each subject and use medical judgment to determine whether the subject can tolerate the imaging procedure

Exclusion Criteria:

Subjects will be excluded from the enrollment if they:

1. Are receiving aggressive treatment with life sustaining measures (e.g. receiving chemotherapy; palliative chemotherapy is allowed)
2. Are known to have a structural brain lesion that would interfere either with PET imaging or pathological assessment (e.g. lesions are typically > 2 cm at their greatest extent and may include stroke, primary or metastatic neoplasm, other tumors or cystic lesions. Subjects with a history of major stroke or traumatic brain injury or other structural lesion as well as cases with a history of primary Central Nervous System (CNS) neoplasm or known metastatic cancer must be discussed with the study sponsor prior to enrollment)
3. Have suspected encephalopathy due to alcoholism or end-stage liver disease
4. Are known to have a Glomerular Filtration Rate below < 15 mL/min
5. Have received an investigational or approved therapy directly targeting amyloid or tau
6. Are females of childbearing potential who are pregnant, lactating or breastfeeding, or who are not using adequate contraception
7. Have implants such as implanted cardiac pacemakers or defibrillators, insulin pumps, cochlear implants, metallic ocular foreign body, implanted neural stimulators, CNS aneurysm clips and other medical implants that have not been certified for MRI, or history of claustrophobia in MRI (in case an MRI is planned to be performed)

Study Design

Enrollment

200 participants

Anticipated

Intervention Model

Single group

Primary purpose

Diagnostic

Interventions and Outcome Measures

Arms

experimental: PI-2620 PET Scan

Interventions

[18F]PI-2620

The radioligand, \[18F\]PI-2620, will be injected intravenously at a dose of 185 MBq ± 20%

Primary outcome measure

  • Diagnostic Efficacy of the visual assessment of [18F]PI-2620 PET imaging, in correctly differentiating tau neurofibrillary pathology associated with AD (NFT Score of B0 or B1 = negative) [ Time Frame: At autopsy, until study completion with an average of 1 year ]

Central Contacts and Locations

Locations

Barrow Neurological Institute

Recruiting

Phoenix, Arizona, United States, 85013

Banner Sun Health Research Institute

Recruiting

Sun City, Arizona, United States, 85352

UC Los Angeles

Recruiting

Los Angeles, California, United States, 90095 - 7370

Esperanza Clinical

Recruiting

Murrieta, California, United States, 92562

Sutter Health

Recruiting

San Francisco, California, United States, 94114

Galiz Research

Recruiting

Hialeah, Florida, United States, 33016

K2 Medical Research

Recruiting

Lady Lake, Florida, United States, 32159

K2 Medical Research

Recruiting

Maitland, Florida, United States, 32751

ClinCloud Research

Recruiting

Melbourne, Florida, United States, 32940

Miami Jewish Health Systems

Recruiting

Miami, Florida, United States, 33137

Charter Research

Recruiting

Winter Park, Florida, United States, 32792

Alzheimer's Disease Center

Recruiting

Braintree, Massachusetts, United States, 02184

Darthmouth-Hitchcock Medical Center

Recruiting

Lebanon, New Hampshire, United States, 07366

Velocity Clinical Research

Recruiting

East Syracuse, New York, United States, 13057

Ichor Research

Recruiting

Syracuse, New York, United States, 13219

Insight Clinical Trials LLC

Recruiting

Beachwood, Ohio, United States, 44131

Valley Medical Research

Recruiting

Centerville, Ohio, United States, 45459

Baylor Research Institute

Recruiting

Dallas, Texas, United States, 75231

Sante Clinical Research

Recruiting

Kerrville, Texas, United States, 78028

Be Well Clinical Studies

Recruiting

Round Rock, Texas, United States, 78681

More Information

Sponsor

Lantheus Biosciences Ltd.

Last update posted

May 22, 2026

Last verified

Dec, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Lantheus Biosciences Ltd. on 2026-05-22.